171 related articles for article (PubMed ID: 18809389)
1. Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor.
Hoffmann K; Sixel U; Di Pasquale F; von Kügelgen I
Biochem Pharmacol; 2008 Nov; 76(10):1201-13. PubMed ID: 18809389
[TBL] [Abstract][Full Text] [Related]
2. Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor.
Hoffmann K; Baqi Y; Morena MS; Glänzel M; Müller CE; von Kügelgen I
J Pharmacol Exp Ther; 2009 Nov; 331(2):648-55. PubMed ID: 19690189
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of the human P2Y13 receptor.
Marteau F; Le Poul E; Communi D; Communi D; Labouret C; Savi P; Boeynaems JM; Gonzalez NS
Mol Pharmacol; 2003 Jul; 64(1):104-12. PubMed ID: 12815166
[TBL] [Abstract][Full Text] [Related]
4. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.
Fagura MS; Dainty IA; McKay GD; Kirk IP; Humphries RG; Robertson MJ; Dougall IG; Leff P
Br J Pharmacol; 1998 May; 124(1):157-64. PubMed ID: 9630355
[TBL] [Abstract][Full Text] [Related]
5. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
[TBL] [Abstract][Full Text] [Related]
6. Identification of a potent inverse agonist at a constitutively active mutant of human P2Y12 receptor.
Ding Z; Kim S; Kunapuli SP
Mol Pharmacol; 2006 Jan; 69(1):338-45. PubMed ID: 16234484
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes.
von Kügelgen I
Pharmacol Ther; 2006 Jun; 110(3):415-32. PubMed ID: 16257449
[TBL] [Abstract][Full Text] [Related]
8. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
[TBL] [Abstract][Full Text] [Related]
9. 6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors.
Crepaldi P; Cacciari B; Bonache MC; Spalluto G; Varani K; Borea PA; Kügelgen Iv; Hoffmann K; Pugliano M; Razzari C; Cattaneo M
Bioorg Med Chem; 2009 Jul; 17(13):4612-21. PubMed ID: 19464902
[TBL] [Abstract][Full Text] [Related]
10. Agonist action of adenosine triphosphates at the human P2Y1 receptor.
Palmer RK; Boyer JL; Schachter JB; Nicholas RA; Harden TK
Mol Pharmacol; 1998 Dec; 54(6):1118-23. PubMed ID: 9855642
[TBL] [Abstract][Full Text] [Related]
11. Cangrelor attenuates coated-platelet formation.
Norgard NB; Hann CL; Dale GL
Clin Appl Thromb Hemost; 2009; 15(2):177-82. PubMed ID: 18796456
[TBL] [Abstract][Full Text] [Related]
12. Effects of P2Y(1) and P2Y(12) receptor antagonists on ADP-induced shape change of equine platelets: comparison with human platelets.
Mateos-Trigos G; Evans RJ; Heath MF
Platelets; 2002; 13(5-6):285-92. PubMed ID: 12189014
[TBL] [Abstract][Full Text] [Related]
13. Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589.
Johnson FL; Boyer JL; Leese PT; Crean C; Krishnamoorthy R; Durham T; Fox AW; Kellerman DJ
Platelets; 2007 Aug; 18(5):346-56. PubMed ID: 17654304
[TBL] [Abstract][Full Text] [Related]
14. ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor.
Kennedy C; Qi AD; Herold CL; Harden TK; Nicholas RA
Mol Pharmacol; 2000 May; 57(5):926-31. PubMed ID: 10779375
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor.
Mao Y; Zhang L; Jin J; Ashby B; Kunapuli SP
Eur J Pharmacol; 2010 Oct; 644(1-3):10-6. PubMed ID: 20599922
[TBL] [Abstract][Full Text] [Related]
17. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents.
Manolopoulos P; Glenn JR; Fox SC; May JA; Dovlatova NL; Tang SW; Thomas NR; Ralevic V; Heptinstall S
Platelets; 2008 Mar; 19(2):134-45. PubMed ID: 18297551
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and signaling properties of endogenous P2Y1 receptors in cystic fibrosis transmembrane conductance regulator-expressing Chinese hamster ovary cells.
Marcet B; Chappe V; Delmas P; Verrier B
J Pharmacol Exp Ther; 2004 May; 309(2):533-9. PubMed ID: 14742736
[TBL] [Abstract][Full Text] [Related]
19. Expression of purinergic P2Y receptor subtypes by INS-1 insulinoma beta-cells: a molecular and binding characterization.
Lugo-Garcia L; Filhol R; Lajoix AD; Gross R; Petit P; Vignon J
Eur J Pharmacol; 2007 Jul; 568(1-3):54-60. PubMed ID: 17509560
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
